

Atty. Dkt. No. 039363-1106

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Artis, et al.

Title:

PDE5A CRYSTAL

STRUCTURE AND USES

Appl. No.:

10/771,833

Filing Date:

2/3/2004

Examiner:

Kim, Alexander D.

Art Unit:

1656

Confirmation

9734

Number:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

ANITA PATEL

(Printed Name)

(Signature)

August 10, 2006

(Date of Deposit)

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment-IDS Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

98/17/2006 CNEGA1

00000010 10771833

01 FC:1806

180.00 OP

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit

card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date CANGUAT 9, 20

FOLEY & LARDNER LLP

Customer No.: 30542

Telephone: (858) 847-6767 Facsimile: (858) 792-6773 ву

Richard J. Warburg Attorney for Applicant Registration No. 32,327

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paper k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

TRADEN	Substitute for	form 1449B	/PTO	Complete if Known			
	INFORMATIO	N DISCLO	SURE	Application Number	10/771,833		
	STATEMENT	BY APPLI	CANT	Filing Date	2/3/2004		
				First Named Inventor	Dean R. Artis		
				Group Art Unit	1656		
	(use as many sh	eets as ne	cessary)	Examiner Name	Kim, Alexander D.		
Sheet	1	of	2	Attorney Docket Number	039363-1106		

U.S. PATENT DOCUMENTS									
Examiner Initials*			U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	Cite No.1	Number	Kind Code ² (if known)						

			UNPUBLISI	HED U.S. PATENT APPLICATION	DOCUMENTS	
Examiner Initials*	Cite	U.S. Patent Ap	•	Name of Patentee or Applicant of Cited Document	Filing Date of	Pages, Columns, Lines, Where Relevant
	No.1	Serial Number	Kind Code ² (if known)		Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Fore Office 3	eign Patent [Number ⁴	Oocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T _e		
			<u> </u>							

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue nu publisher, city and/or country where published.			
	A1	DYM et al., Molecular docking of competitive phosphodiesterase inhibitors, Molecular Pharmacology, 61:20-25, 2002		
	A2	HADDAD et al., Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (Interleukin-6 and tumor necrosis factor-α) Biosynthesis in alveolar epithelial cells, The Journal of Pharmacology and Experimental Therapeutics, 300:559-566, 2002		
	А3	HUAI et al., Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity, Structure, 11:865-873, 2003		
	A4	MANNING et al., Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B, British Journal of Pharmacology, 128:1393-1398, 1999		

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for	form 1449B.	/PTO	Complete if Known		
	INFORMATIO	N DISCLO	SURE	Application Number	10/771,833	
	STATEMENT	BY APPLI	CANT	Filing Date	2/3/2004	
				First Named Inventor	Dean R. Artis	
				Group Art Unit	1656	
	(use as many sh	eets as ne	cessary)_	Examiner Name	Kim, Alexander D.	
Sheet	2	of	2	Attorney Docket Number	039363-1106	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A5 -	TEJADA et al., The phosphodiesterase inhibitory selectivity and the <i>in vitro</i> and <i>in vivo</i> potency of the new PDE5 inhibitor vardenafil, International Journal of Impotence Research, 13:282-290, 2001	

	 ·		
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.